spec sheet3 rows
Vitagerpavac is a Russian therapeutic vaccine made from inactivated herpes simplex virus types 1 and 2 grown on a Vero cell line, given as a course of intradermal injections to reduce how often recurrent herpes returns; it is registered only in Russia and there is no independently replicated evidence that it works.
- Vitagerpavac is a Russian-manufactured inactivated (formalin-killed) whole-virion vaccine against herpes simplex virus types 1 and 2, registered in the Russian Federation for reducing recurrences of chronic herpetic infection; it is not licensed by the FDA, the EMA or the MHRA.
- A PubMed search of the trade name 'Vitagerpavac' returns zero indexed records (searched 2 August 2026), so there is no indexed randomised trial, no indexed cohort study and no indexed mechanistic characterisation of this specific product.
- The nearest indexed literature is Russian-language work on an earlier killed HSV-1/HSV-2 culture vaccine used as an immunocorrective agent in chronic herpetic infection (PMID 10876868, Zh Mikrobiol Epidemiol Immunobiol 1999), but that paper describes a predecessor or related preparation and is not an evaluation of Vitagerpavac, so it is not cited here as evidence for this product.
- No target rows are given because no measured interaction of this product with any human receptor, enzyme or transporter has been published in the indexed literature; as a whole inactivated viral vaccine its presumed action is adaptive immune priming rather than binding a molecular target.
- By contrast, HSV vaccine candidates that have been rigorously tested in the indexed literature (glycoprotein D subunit vaccines) failed their pivotal efficacy trials, so an unevidenced herpes vaccine should be treated with the scepticism that history warrants.
Mechanism
Inactivated whole virus antigen is intended to raise HSV specific cell mediated immunity so that reactivation from the sensory ganglia is suppressed. The context that matters is that no therapeutic herpes vaccine has ever succeeded in a large independent trial, which is the standard the Russian registration was not held to.
Safetyrisks and cautions, not medical advice
a vaccine; it is given as a course of intradermal injections by a clinician, is contraindicated during an active outbreak, in pregnancy and in immunodeficiency, needs a cold chain an import shipment cannot provide, and is licensed only in Russia
Subjective profileweighing the evidence above
The sourcing question is left unanswered here, and the reasons are not subtle. It is a vaccine of inactivated herpes virus given as a course of intradermal injections by a clinician, it needs a cold chain no import shipment maintains, and it is contraindicated during an active outbreak, in pregnancy and in immunodeficiency. The scientific position matters as much as the logistics: no therapeutic herpes vaccine has ever succeeded in a large independent trial, and the Russian registration was not held to that standard. This entry documents what the product is; it is not a suggestion to obtain one.
Resources
No suppliers are provided for compounds like this. This entry is here for reference.
Reviews
My notesprivate to this device
Notes and cautions
- There is no indexed safety evidence for Vitagerpavac: no published randomised trial, no pharmacovigilance dataset outside the Russian Federation, and no regulatory review by the FDA, EMA or MHRA.
- General principles for inactivated whole-virion vaccines apply; injection-site reactions, fever and hypersensitivity including anaphylaxis are the expected classes of risk, and live-vaccine contraindications do not apply since the preparation is killed; but none of this has been quantified for this product.
- It should not be presented as a treatment or prophylaxis with demonstrated benefit for herpes simplex, and the honest description is that the evidence base is absent rather than negative.